CPA
CMPX icon

Capital Performance Advisors’s Compass Therapeutics CMPX Stock Holding History

Capital Performance Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-172
Closed -$316 – 676
2024
Q3 		$316 Buy
+172
New +$214 ﹤0.01% 2441

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Performance Advisors's CMPX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Compass Therapeutics (CMPX) in Q4 2024, closing a stake of 172 shares — an estimated $316 sold.

Capital Performance Advisors first reported a position in CMPX in Q3 2024 and held it in 1 quarter. The position peaked at $316 in Q3 2024. 92 funds tracked by Wall St. Rank hold CMPX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Compass Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 172 Compass Therapeutics shares in Q4 2024, an estimated $316.
  • Capital Performance Advisors first reported a position in Compass Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Compass Therapeutics position peaked at $316 in Q3 2024.
  • 92 funds tracked by Wall St. Rank held Compass Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.